Orchard Therapeutics PLC (ORTX)

NASDAQ: ORTX · Delayed Price · USD
-0.005 (-1.12%)
At close: May 25, 2022 4:00 PM
0.013 (2.740%)
After-hours:May 25, 2022 7:50 PM EDT

Company Description

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States.

The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.

It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia.

Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB.

It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema.

The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Orchard Therapeutics PLC
Orchard Therapeutics Logo
CountryUnited Kingdom
IPO DateOct 31, 2018
SectorHealth Care

Contact Details

108 Cannon Street
London EC4N 6EU
United Kingdom
Phone44 20 3 808 8286

Stock Details

Ticker SymbolORTX
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001748907

Key Executives

Dr. Bobby Gaspar M.D., Ph.D.Chief Executive Officer, Member of Scientific Advisory Board and Executive Director
Frank E. ThomasPresident and Chief Operating Officer
Dr. Nicoletta Loggia Ph.D.Chief Technical Officer
Dr. Fulvio Mavilio Ph.D.Chief Scientific Officer
Renee T. LeckDirector of Investor Relations
Benjamin NavonDirector of Corporate Communications
John CerioChief Human Resource Officer
Dr. Anne Dupraz-PoiseauChief Development Officer
Robin KenselaarSenior Vice President and GM of EMEA Commercial Operations
Braden ParkerChief Commercial Officer

Latest SEC Filings

Apr 8, 20228-KCurrent report
Apr 5, 20224Statement of changes in beneficial ownership of securities
Apr 4, 20224Statement of changes in beneficial ownership of securities
Mar 30, 2022S-3Registration statement under Securities Act of 1933
Mar 30, 202210-KAnnual report [Section 13 and 15(d), not S-K Item 405]
Mar 30, 2022POSASRPost-effective Amendment to an automatic shelf registration statement
Mar 30, 20228-KCurrent report
Feb 14, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Feb 14, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Feb 11, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
View All SEC Filings